Drugs /

pacritinib

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Oral JAK2 inhibitor SB1518 competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity.

Clinical Trials

View Clinical Trials for pacritinib

Pacritinib has been investigated in 6 clinical trials, of which 3 are open and 3 are closed. Of the trials investigating pacritinib, 2 are phase 1 (0 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open).

FLT3 Mutation, IRAK1 Fusion, and IRAK1 Mutation are the most frequent biomarker inclusion criteria for pacritinib clinical trials.

Peripheral T-cell lymphoma, primary cutaneous T-cell non-hodgkin lymphoma, and acute myeloid leukemia are the most common diseases being investigated in pacritinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pacritinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Pacritinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pacritinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
sb1518, sb 1518, oral jak2 inhibitor sb1518, sb-1518
Drug Categories [2]:
JAK inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
FLT3, JAK2
NCIT ID [1]:
C78837

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.